CVS Health (CVS) Downgraded by Vetr to Hold

Vetr lowered shares of CVS Health (NYSE:CVS) from a buy rating to a hold rating in a research note published on Thursday. Vetr currently has $77.11 price target on the pharmacy operator’s stock.

CVS has been the subject of several other research reports. Needham & Company LLC restated a hold rating on shares of CVS Health in a research note on Sunday, September 10th. Oppenheimer restated a buy rating and issued a $95.00 target price on shares of CVS Health in a research note on Monday, October 9th. Leerink Swann restated an outperform rating and issued a $85.00 target price (down previously from $90.00) on shares of CVS Health in a research note on Tuesday, November 7th. SunTrust Banks set a $85.00 target price on CVS Health and gave the stock a buy rating in a research note on Thursday, October 12th. Finally, Citigroup set a $76.00 target price on CVS Health and gave the stock a hold rating in a research note on Monday, December 4th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $86.42.

Shares of CVS Health (CVS) traded up $3.12 on Thursday, reaching $78.25. The company had a trading volume of 10,037,748 shares, compared to its average volume of 8,577,733. CVS Health has a 52 week low of $66.45 and a 52 week high of $84.72. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67. The stock has a market cap of $79,260.00, a price-to-earnings ratio of 16.17, a P/E/G ratio of 1.29 and a beta of 0.90.

CVS Health (NYSE:CVS) last issued its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, topping the consensus estimate of $1.49 by $0.01. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The business had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. During the same quarter last year, the company earned $1.64 EPS. The firm’s revenue was up 3.5% compared to the same quarter last year. sell-side analysts predict that CVS Health will post 5.9 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 2nd. Stockholders of record on Wednesday, January 24th will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Tuesday, January 23rd. This represents a $2.00 dividend on an annualized basis and a dividend yield of 2.56%. CVS Health’s dividend payout ratio (DPR) is presently 41.32%.

In other news, EVP Lisa Bisaccia sold 29,445 shares of CVS Health stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the completion of the sale, the executive vice president now owns 15,556 shares in the company, valued at approximately $1,166,700. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 0.61% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the company. Fulton Bank N.A. lifted its position in CVS Health by 3.4% in the 4th quarter. Fulton Bank N.A. now owns 32,490 shares of the pharmacy operator’s stock worth $2,356,000 after buying an additional 1,077 shares during the last quarter. Beacon Financial Group lifted its position in CVS Health by 97.8% in the 4th quarter. Beacon Financial Group now owns 126,945 shares of the pharmacy operator’s stock worth $9,204,000 after buying an additional 62,765 shares during the last quarter. Prudential Financial Inc. lifted its position in CVS Health by 13.1% in the 3rd quarter. Prudential Financial Inc. now owns 3,332,567 shares of the pharmacy operator’s stock worth $271,004,000 after buying an additional 386,036 shares during the last quarter. Atlantic Trust Group LLC lifted its position in CVS Health by 4.5% in the 3rd quarter. Atlantic Trust Group LLC now owns 1,484,499 shares of the pharmacy operator’s stock worth $120,719,000 after buying an additional 64,123 shares during the last quarter. Finally, Parametric Portfolio Associates LLC lifted its position in CVS Health by 8.9% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 4,208,978 shares of the pharmacy operator’s stock worth $342,274,000 after buying an additional 343,543 shares during the last quarter. Hedge funds and other institutional investors own 81.63% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://transcriptdaily.com/2018/01/05/cvs-health-cvs-downgraded-by-vetr-to-hold.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply